

## OPINION

# The recurrent architecture of tumour initiation, progression and drug sensitivity

Andrea Califano and Mariano J. Alvarez

**Abstract** | Recent studies across multiple tumour types are starting to reveal a recurrent regulatory architecture in which genomic alterations cluster upstream of functional master regulator (MR) proteins, the aberrant activity of which is both necessary and sufficient to maintain tumour cell state. These proteins form small, hyperconnected and autoregulated modules (termed tumour checkpoints) that are increasingly emerging as optimal biomarkers and therapeutic targets. Crucially, as their activity is mostly dysregulated in a post-translational manner, rather than by mutations in their corresponding genes or by differential expression, the identification of MR proteins by conventional methods is challenging. In this Opinion article, we discuss novel methods for the systematic analysis of MR proteins and of the modular regulatory architecture they implement, including their use as a valuable reductionist framework to study the genetic heterogeneity of human disease and to drive key translational applications.

There is an intriguing yet largely unexplored paradox in cancer. On the one hand, transcriptional programmes are highly conserved across samples that represent the same tumour subtype<sup>1</sup> — even compared with normal tissue (FIG. 1a) — suggesting the existence of relatively stable tumour states. On the other hand, the genetic and epigenetic alterations (henceforth referred to as genomic alterations) that determine these states are remarkably heterogeneous on a sample by sample basis (BOX 1).

Consistent with these observations, although genomic alterations represent valuable predictors of targeted inhibitor sensitivity against the corresponding oncoproteins, they have proved less effective in stratifying more general properties of cancer, such as tumour subtype, metastatic potential and clinical outcome<sup>2,3</sup>, which are more often captured by transcriptional or proteomic profiles<sup>4,5</sup> (BOX 1). For example, immunohistochemistry assays, as well as gene expression-based tests such as Oncotype DX and MammaPrint<sup>6</sup>,


are routinely used in the clinic to assess the risk of breast cancer recurrence following hormonal therapy.

The ability of tumours to present similar transcriptional signatures, despite having radically distinct somatic mutational profiles, suggests the existence of regulatory mechanisms that are responsible for decoupling (that is, buffering) the tumour cell state from its genetic, epigenetic and signalling determinants<sup>7,8</sup>. Specifically, this Opinion article provides an overview of the emergence of a universal gene-regulatory architecture (henceforth referred to as oncotecture), in which a handful of master regulator (MR) proteins — organized into tightly autoregulated tumour checkpoint modules — implement and maintain the transcriptional state of a tumour cell largely independent of initiating events, as well as of endogenous and exogenous perturbations<sup>7,8</sup>. Much like a highway checkpoint, these modular structures canalize the effect of mutations and other aberrant signals in their upstream pathways to implement key

downstream transcriptional programmes (FIG. 1b). Thus, although individual MR proteins are highly tumour specific<sup>9–11</sup>, the resulting tumour checkpoint oncotecture is virtually tumour independent<sup>7</sup>.

The term MR was initially introduced by developmental biologists to describe gene products (mostly transcription factors) at the top of regulatory hierarchies that are both necessary and sufficient to induce morphogenesis<sup>12</sup> or specific steps in lineage differentiation<sup>13</sup>. By contrast, cancer biologists have adopted a looser definition of the term to indicate genetic determinants or functional drivers, the aberrant activity of which is sufficient — yet not strictly necessary — to induce transformation. According to the latter, *TP53* (which encodes p53) and *ERBB2* (which encodes HER2) are often presented as cancer MRs<sup>14,15</sup>, even though many alternative genomic alterations may induce transcriptional tumour states that are virtually indistinguishable from those in which those genes are mutated (BOX 1). For instance, several tumours classified as basal-like or HER2<sup>+</sup> by gene expression profile analysis lack the hallmark genetic alterations in *TP53* and *ERBB2*, respectively<sup>16</sup>. In this Opinion article, not only do we adopt the stricter MR definition from developmental biology but we further require MRs to directly regulate the transcriptional state of the tumour cell (FIG. 1b). Under this definition, a classic cancer driver such as p53 may not be considered a MR unless it is necessary and sufficient to implement a subset of tumours with a common transcriptional signature and it directly participates in its signature regulation. By contrast, the MYC proto-oncoprotein, the locus of which is translocated in 100% of Burkitt lymphomas<sup>17</sup> and which regulates their signature<sup>18</sup>, would emerge as a bona fide MR protein in that context.

This stricter terminology is not arbitrary. Instead, it is necessary to address the currently ambiguous use of the term in the literature, thus making identification of MR proteins a more rational and systematic process. Consistently, it separates the methodologies and studies discussed in this Opinion article from those aimed at identifying more loosely defined functional drivers or genetic determinants of cancer, for instance, by integrating mutational and gene expression



**Figure 1 | The architecture of tumour checkpoints.** **a** | The probability densities of normal and transformed cells are shown in a principal component (PC) projection that captures most of the sample variability of four tumour types: colorectal adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), uterine corpus endometrial cancer (UCEC) and prostate adenocarcinoma (PRAD). These distributions show a clear single-peak structure, suggesting that the regulatory logic of the tumour cell is effective in avoiding occupancy of states that are far away from the mean. Considering that cancer tissue may also be contaminated by extensive lymphocytic and stromal cell infiltration, the variance of the normal and tumour-associated distributions is of quite comparable magnitude. A comprehensive inventory of all tumour types in The Cancer Genome Atlas (TCGA) reveals that only a handful — such as head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP) and liver hepatocellular carcinoma (LIHC) — present with substantially greater variance than the corresponding normal tissue. **b** | The proposed regulatory architecture implemented by master regulator (MR) proteins in tumour checkpoints is shown. MRs (blue spheres in shaded area) represent proteins the concerted, aberrant activity of which is both necessary and sufficient for cancer cell state maintenance. Their aberrant activity is induced by genes in their upstream pathways that are mutated in a specific patient (purple spheres) selected from a larger repertoire of candidate driver genes (green spheres), the mutation of which is recurrently detected in large cohorts. Passenger mutations (pale blue spheres) that are

not upstream of MRs have no effect on tumour checkpoint activity and thus on the specific phenotype that the checkpoint regulates. Arrows in this diagram show regulatory and signalling interactions, that is, how one gene product regulates other gene products. Black arrows represent crucial top-down interactions leading from patient mutations first to activation of MR proteins in the tumour checkpoint and then to activation of downstream genetic programmes that are required for tumour phenotype presentation. Grey and blue arrows represent additional regulatory interactions that do not affect and are not affected by tumour checkpoint MRs, respectively. Dashed arrows represent feedback loops implemented either between the MR layer and the upstream modulators or between genes regulated by MR proteins and upstream MR modulators. The MR protein module in the shaded area represents the tumour checkpoint. Pink spheres represent genes that are differentially expressed as a result of the aberrant activity of MR proteins in the tumour checkpoint (that is, the tumour gene expression signature). Lightning bolts represent potential therapeutic interventions using pharmacological inhibitors. Inhibiting oncoproteins mutated in a large fraction (for example, 90%) of tumour subclones will cause relapse owing to the presence of rare, alternative subclones harbouring either alternative or bypass mutations. A bypass mutation is a mutation that activates the pathway downstream of the pharmacological intervention point. By contrast, inhibiting the tumour checkpoint may represent a more effective strategy, as it captures the effect of all upstream mutations.

profiles<sup>19</sup>, by network hub analysis<sup>20</sup> or by other integrative network analyses<sup>21</sup>. A specific advantage of such stricter nomenclature is its ability to differentiate proteins representing effective pharmacological targets because of their necessary and direct role in maintaining tumour state from those that may be only sufficient, thus representing less crucial targets.

**Cellular homeostasis and cancer**

A large subset of the cell's regulatory logic presides over homeostasis, a concept that can be traced back to the French physiologist Claude Bernard in 1865 and its refinement by Walter Cannon in 1929 (REF. 22). Homeostasis was originally defined as the set of regulatory processes that ensure the overall stability of a system, independent

of endogenous and exogenous variables. This concept plays an especially important part in cell physiology, where its main role is to collapse a universe of potential cell states into a finite number of energetically and physiologically viable ones, each representing a distinct cell lineage or precursor stage. This process, better known as Waddington's canalization<sup>23</sup>, was initially

Box 1 | The tumour subtype paradox


The past decade has witnessed marked proliferation of tumour subtypes, mostly identified by gene expression clustering. For example, breast cancer has been divided into 4–10 subtypes<sup>4,5</sup> and glioma into 3 or 4 subtypes<sup>3,79</sup>. Yet, there is little consistency between expression-based subtypes and stratification based on genetic alterations. For example, consider the breast cancer cohort in *The Cancer Genome Atlas* (TCGA; see Further information). We used standard unsupervised cluster analysis<sup>108</sup> to identify the best four clusters based on distinct data types — somatic coding mutations (SCMs; part **a** of the figure), copy number variants (CNVs; part **b** of the figure), gene expression profiles (GEPs; part **c** of the figure) and master regulator activity (MRA; part **d** of the figure). This enables comparison of clustering results across these four data types and also against the clinically relevant Perou classification<sup>16</sup> — including luminal A (LumA), luminal B (LumB), HER2<sup>+</sup> (HER2) and basal-like (Basal). Silhouette score (shaded waterfall plots) and Perou classification (colour coded bars) are shown above and below the heat maps in parts **a–d**, respectively.

Surprisingly, but consistent with the tumour checkpoint hypothesis, three out of four of the clusters identified by either SCM or CNV analysis presented relatively low silhouette score (SS) significance, suggesting low internal consistency, and relatively low overlap with GEP-based clusters. One SCM cluster was not even statistically significant ( $SS_{SCM} = -0.01$ ,  $P = 1$ ). Furthermore, part **e** shows the fraction of overlapping samples (above the expected background), for each cluster compared with each Perou subtype. As shown, the Perou classification was poorly recapitulated by SCM and CNV analysis, except for the Basal (SCM) and LumA (CNV) subtypes. Compared with SCM and CNV analysis, unsupervised GEP analysis improved cluster significance as well as Perou classification consistency, yet failed to fully differentiate between LumA, LumB and HER2 samples (parts **c** and **e** of the figure), which are intermixed in three out of four clusters. By contrast, MRA clustering (part **d** of the figure) not only improved the statistical significance of the four inferred clusters — a measure of cluster self-consistency — but also most closely recapitulated the Perou classification, with highly significant enrichment of cluster 1 (Basal,  $P = 3.1 \times 10^{-17}$ ), cluster 2 (LumA,  $P = 3.1 \times 10^{-19}$ ), cluster 3 (LumB,  $P = 3.6 \times 10^{-4}$ ) and cluster 4 (HER2,  $P = 2.6 \times 10^{-14}$ ).

These data suggest that subtype proliferation may have resulted, at least in part, from three sources

of variability: noisy gene expression profiles (part **c**), independent clustering and heterogeneity of genetic alterations (parts **a** and **b**), potential coexistence of distinct tumour states in the same mass (tumour heterogeneity<sup>107</sup>) and stroma infiltration. Indeed, most tumour subtypes (including those of Perou) were identified by analysing a subset of the genes rather than by unbiased genome-wide analysis — with slight changes in gene selection producing significant variability in subtype identification.

To show the poor reproducibility of gene expression measurement, we plotted the distribution of the 10 most differentially expressed genes in each sample across all other same-subtype samples (part **f** of the figure). As shown, high differential expression in one sample is not predictive of differential expression across the full subtype. By contrast, the rank of the 10 most differentially active proteins in each sample, as inferred by Virtual Inference of Protein Activity by Enriched Regulon Analysis (VIPER), is extremely well conserved across the corresponding subtypes. Consistently, the most differentially active proteins in the LumA and LumB subtypes — see, for example, forkhead box A1 (FOXA1), GATA binding protein 3 (GATA3), oestrogen receptor 1 (ESR1) — represent established luminal lineage driver and subtype-specific tumour dependencies. As such, they are bona fide members of the LumA and LumB tumour checkpoints.



introduced to explain the robustness and stability of developmental phenotypes when confronted by genetic, epigenetic and environmental perturbations. It was later broadened to include the global mechanisms that preside over the stability of cellular phenotypes<sup>24</sup>.

The general view is that homeostasis is disrupted in disease, including in cancer<sup>25,26</sup> (FIG. 2). And yet, tumour-associated states seem to be remarkably stable (FIG. 1 a), suggesting that some form of stability control, albeit a dysregulated one, must still be at play. Indeed, similar to their normal counterpart, cancer cell states — as represented by their transcriptional signatures — are rather impervious to endogenous and exogenous variability, from germline and somatic variants, to pharmacological perturbations, microenvironment signals, temperature changes and nutrient availability. For instance, xenograft tumours in mice and even cancer cell lines can maintain a relatively high-fidelity

representation of the transcriptional state of the original tumour, despite aberrant ploidy, mutational drift and massive changes in the repertoire of microenvironment signals to which they are exposed<sup>27</sup>. Similarly, cancer cells are easier to culture outside their original milieu than normal cells. Indeed, more than 1,000 cancer cell lines have been successfully established, compared with only a handful of cell lines representing immortalized normal tissue<sup>28</sup>.

Despite overwhelming evidence, however, a systematic investigation of the dystatic (short for dysregulated homeostatic) logic that ensues from transformation has not been undertaken. Recent results suggest that dystatic cell states may be implemented by a handful of tumour-specific MR proteins — working cooperatively within tight modular structures (tumour checkpoints) — the aberrant activity of which is necessary and sufficient for tumour phenotype presentation and maintenance<sup>7,9–11,29,30</sup>. If this hypothesis were further confirmed,

these tumour checkpoints and associated MRs would constitute a novel class of mechanistic biomarkers and therapeutic targets<sup>11,29–31</sup> and would further link cancer and development.


**The tumour checkpoint hypothesis**

Diffuse large B cell lymphoma (DLBCL) represents an ideal context in which to explore the tumour checkpoint hypothesis. Indeed, although never mutated in this malignancy, the canonical nuclear factor- $\kappa$ B (NF- $\kappa$ B) heterodimer (p50–RELA) represents a crucial dependency of the activated B cell (ABC) but not of the germinal centre B cell (GCB) subtype of DLBCL<sup>32</sup>. Indeed, aberrant NF- $\kappa$ B activity was shown to arise from several mutations in its upstream pathways, including in TNF-induced protein 3 (*TNFAIP3*), myeloid differentiation primary response 88 (*MYD88*), TNF receptor associated factor 2 (*TRAF2*), *TRAF5*, *CD79A*, *CD79B*, *MAP3K7* (also known as *TAK1*), *TNFRSF11A* (which encodes RANK) and caspase recruitment domain family member 11 (*CARD11*)<sup>8,33,34</sup> (FIG. 3). Moreover, NF- $\kappa$ B activity was essential for tumour viability only in DLBCL cells harbouring these events<sup>8</sup>. Finally, NF- $\kappa$ B transcriptional targets (as assessed by a literature search) were significantly differentially expressed in the ABC-DLBCL signature<sup>8</sup>, supporting its direct role in regulating subtype-specific programmes. Taken together, these findings support the role of the p50–RELA complex as a non-oncogene dependency<sup>35</sup> and MR protein, consistent with our definition.

Although intriguing, however, these findings are not easily extended to other tumour types. Specifically, initial identification of NF- $\kappa$ B was more the product of investigator ingenuity than of generalizable methodologies<sup>32</sup>. Additionally, detailed information about pathways upstream of arbitrary candidate MR proteins is frequently unavailable. Thus, systematic elucidation of MR proteins requires the development of more effective methodologies to reconstruct and interrogate the genome-wide regulatory logic of the cancer cell.


**MR and tumour checkpoint elucidation**

Defining MR proteins as mechanistic regulators of the transcriptional signatures that define distinct tumour states helps with their systematic identification. Specifically, it implies that the transcriptional targets of a bona fide MR protein must be enriched in genes that are differentially expressed in the cellular phenotype of interest (for example, tumour subtype, tumorigenesis,



**Figure 2 | Dysregulation of homeostatic control following malignant transformation and activation of dystatic control mechanisms that are responsible for the stability of tumour cell state.** This figure shows how normal cell physiology is determined by the energetic landscape of its regulatory networks, enabling cells to follow specific developmental trajectories that are highly insensitive to genetic, epigenetic and environmental variability, thus achieving stable end point states. This process, also known as Waddington canalization<sup>23</sup>, is illustrated in a cartoon showing differentiation from haematopoietic stem cell (HSC), to multi-lymphoid progenitor (MLP) to a fully differentiated human B cell as a set of transitions to states of progressively lower energy and thus higher stability. Disruption of this regulatory landscape by genetic alterations and environmental signals leads to physiological state loss and emergence of novel, stable disease states, for example, diffuse large B cell lymphoma (DLBCL). When multiple, quasi-isoeenergetic states emerge, they can lead to coexistence of cells representing distinct tumour phenotypes in the same tumour mass or to tumour cell reprogramming to different states following treatment, a process known as tumour plasticity. For example, it has been shown that cells representing both the mesenchymal and the proneural subtype of glioma can coexist in the same tumour<sup>107</sup> and that a small fraction of cells treated with tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) transiently reprogramme to a TRAIL-resistant state<sup>133</sup>. Whereas normal cell homeostasis presides over the stability of physiological cell states, by making them difficult to escape, we propose that a dysregulated form of these stability control processes (that is, tumour dystasis) is responsible for the stability of tumour-associated cell states and is mechanistically implemented by a small number of master regulator (MR) proteins in a tumour checkpoint.





**Figure 3 | Diverse genetic alterations in upstream pathways contribute to aberrant NF- $\kappa$ B activity in DLBCL.** Systematic analysis of genes in pathways upstream of the nuclear factor- $\kappa$ B (NF- $\kappa$ B) complex revealed a large repertoire of diffuse large B cell lymphoma (DLBCL)-specific genetic alterations in B cell receptor (BCR) and myeloid differentiation primary response 88 (MYD88) pathways. The presence of these mutations leads to aberrant activation of the canonical p50–RELA heterodimer and associated tumour dependency. These mutations, which are more frequent in the activated B cell (ABC) subtype of DLBCL, have provided the rationale for the

clinical development of several BCR pathway inhibitors, such as ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor. CARD11, caspase recruitment domain family member 11; IFN, interferon; IL, interleukin; IRAK, IL-1 receptor-associated kinase; IRF4, interferon regulatory factor 4; ITAM, immune receptor tyrosine-based activation motif; JAK1, Janus kinase 1; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; PKC, protein kinase C; STAT, signal transducer and activator of transcription; TIR, Toll–interleukin receptor; TRAF6, TNF receptor associated factor 6. Adapted with permission from REF. 134, Nature Publishing Group.


metastatic progression and drug sensitivity). More specifically, the positively regulated targets of an aberrantly activated MR protein should be overexpressed, whereas the negatively regulated (that is, repressed) ones should be underexpressed (FIG. 4). This provides a straightforward rationale for computational MR protein inference, using enrichment analysis methods such as the Kolmogorov–Smirnov test<sup>36</sup> — as implemented by gene set enrichment analysis (GSEA)<sup>37</sup> or by its analytical derivatives, such as analytical rank-based enrichment analysis (aREA)<sup>38</sup>. Indeed, when coupled with accurate, *de novo* identification of tissue-specific protein targets (regulons), this represents the conceptual foundation of the Master Regulator Inference Algorithm (MARINA)<sup>10,39</sup> and of its extension to single sample analysis, Virtual Inference of Protein Activity by Enriched Regulon Analysis (VIPER)<sup>38</sup>. To further increase accuracy and sensitivity, these algorithms specifically account for target directionality (that is, activated versus repressed targets), regulon overlap between candidate MR protein pairs and target inference confidence<sup>38</sup>.

Most of the published studies on the unbiased inference of MR proteins as mechanistic regulators of disease cell state (even excluding those from our laboratory to avoid bias) either use the MARINA and VIPER algorithms directly (for example, see REFS 40–44) or rely on slightly modified versions (for example, see REFS 45–47). By contrast, as mentioned above, there are many network-based algorithms to identify key regulators, drivers and pathways involved in tumorigenesis that are not based on mechanistic regulation of target genes (for example, see REFS 19,21). These are extensively covered by earlier reviews<sup>48,49</sup> and will not be further discussed here.

MR analyses have helped elucidate proteins that regulate tumour-associated phenotypes as diverse as predisposition<sup>40,44</sup>, subtype-specific tumorigenesis<sup>10,43,50,51</sup>, progression to aggressive or metastatic disease<sup>9,11,12,45,47,52</sup>, stroma-specific regulation of tumour outcome<sup>41</sup> and drug resistance<sup>29,30</sup>, most of which have been experimentally validated. In addition, their use in non-cancer phenotypes has helped to elucidate an equivalent disease checkpoint

architecture in neurological phenotypes — including amyotrophic lateral sclerosis (ALS)<sup>53</sup>, Alzheimer disease<sup>7,54</sup>, Parkinson disease<sup>55</sup> and alcohol addiction<sup>56</sup> — and in developmental phenotypes, from regulation of germinal centre formation<sup>39</sup> to stem cell pluripotency<sup>57</sup>. As briefly summarized below, these examples further outline the role of tumour checkpoint MRs in regulating disease dystasis and their unique nature compared with their physiological counterpart involved in homeostatic control.

Clearly, accurate transcriptional target inference, using reverse engineering methodologies, is crucial to the effective elucidation of candidate MR proteins and merits explicit mention (see also BOX 2). Postgenomic research has seen intense interest in the systematic dissection of the transcriptional and signalling logic of cancer cells (henceforth termed regulatory logic)<sup>48,53,55–57</sup>, including its transcriptional<sup>58–60</sup>, post-transcriptional<sup>61–63</sup> and post-translational<sup>64–68</sup> layers. These methods were first developed and validated in bacteria<sup>69</sup> and yeast<sup>70,71</sup> and then extended to mammalian cells<sup>21,59</sup>, thus complementing



**Figure 4 | Protein activity inference from the expression of its regulatory targets.** **a** | Protein activity is the ultimate result of a complex cascade of molecular processes, from transcription and translation, to post-translational modification, complex formation and localization to appropriate subcellular compartments. As a result, there are no individual assays that can accurately measure protein activity in proteome-wide fashion. Instead, we have proposed that an accurate estimator of protein activity is represented by the gene expression of its transcriptional targets, that is, its regulon. This rationale is implemented by the Virtual Inference of Protein Activity by Enriched Regulon Analysis (VIPER) algorithm, based on transcriptional targets inferred by reverse engineering algorithms such as Algorithm for the Accurate Reconstruction of Cellular Networks (ARACNe). **b** | When a protein is inactive its targets are randomly distributed in terms of differential expression. **c** | By contrast, when the same protein is aberrantly activated, its positively regulated targets become significantly overexpressed and its repressed targets become underexpressed. This can be effectively and quantitatively assessed by gene expression enrichment analysis methods. EGFR, epidermal growth factor receptor.

pre-existing literature-curated models<sup>72</sup> and large-scale experimental assays<sup>73</sup>. The Algorithm for the Accurate Reconstruction of Cellular Networks (ARACNe)<sup>59</sup> was the first of its kind to be experimentally validated in mammalian cells<sup>10,39,57,74</sup> and has been among the most frequently used to infer regulatory targets for MR analysis. However, various alternative approaches have also been popular, from Bayesian networks<sup>75</sup> to co-expression network integration with chromatin immunoprecipitation–sequencing (ChIP–seq) assays<sup>47</sup>. To achieve high accuracy, all these methods require relatively large collections ( $n \geq 100$ ) of gene expression profiles representing a specific cellular context, under conditions that induce broad gene expression variability, such as from genetically heterogeneous tumour samples<sup>10</sup>

or from concomitant genetic and small molecule perturbations<sup>9</sup>. Reverse engineering methods have been extensively discussed in several reviews<sup>48,49,76</sup> and will not be further discussed in this Opinion article.

**Limitations and potential improvements.**

An important question arises as to the technical limitations of MR analysis methods and their reliance on accurate identification of transcriptional targets. A key problem is the considerable dependence of protein targets on tissue context. Indeed, MR targets are affected both by their tissue-specific epigenetic activation or inactivation and by the availability or mutation of cofactors participating in regulatory complexes<sup>66,77,78</sup>. This highlights the need for more sophisticated reverse

engineering methodologies. Indeed, based on thorough benchmarking, activity changes can be accurately measured for only ~70% of transcriptional regulators and ~60% of signal transduction proteins on average<sup>38</sup>. Although this is certainly adequate to support discovery of many novel mechanisms, it is still susceptible to substantial false-positive and false-negative inferences. Consistent with these observations, the use of tissue-specific regulatory models (interactomes) has proved crucial, as statistical significance of inferred MRs decreases when mismatched models are used<sup>9,38</sup>. Indeed, differential protein activity following short hairpin RNA (shRNA)-mediated silencing of transcription factor proteins in different tumour contexts was effectively detected using regulatory models generated from the same tissue context but not from mismatched tissues (BOX 2). Interestingly, the advent of efficient and economical single-cell profiling may herald a new era in network reverse engineering as it will avoid averaging over key processes (for example, cell cycle) and cell states (for example, tumour and stroma). This will help to avoid typical limitations imposed by intratumoural heterogeneity, such as stroma and immune cell infiltration, thus producing more accurate gene regulatory models and improving the accuracy of MR identification, which is substantially degraded when tumour cellularity drops below 70%.

An additional limitation is the complexity of inferring the activity of proteins that share a substantial subset of their regulatory targets. Although specific solutions to this problem have been proposed<sup>38,39</sup>, the combinatorial complexity of target regulation is still not completely addressed, potentially resulting in false-positive findings requiring substantial experimental validation. Finally, a crucial issue is represented by the inference of protein activity in a dynamic context — for example, following a drug perturbation — rather than in regimes approaching cellular equilibrium. In these transient conditions, the correlation between mRNA abundance and protein abundance may be time delayed or even inverted. Ultimately, we foresee that more specialized kinetic models will be required to describe the relationship between target mRNA abundance and protein activity, leading to a more effective generation of dynamic MR inference algorithms.

**MR discovery in cancer biology**

The following sections describe some crucial applications of MR analysis and some of the general principles that have consistently emerged from multiple MR studies.

Box 2 | Alternative procedures for network reverse engineering and analysis

Reverse engineering of regulatory networks represents a hallmark of systems biology, resulting in the development of hundreds of algorithms. Most of these algorithms fit one of the following five categories<sup>109</sup>: experimental maps, describing physical molecular interactions, such as protein–protein<sup>67,110,111</sup> and protein–DNA interactions<sup>112,113</sup>; optimization-based approaches, searching for network topologies that optimally explain the observed data<sup>70,114</sup>; differential equation-based kinetic models, representing the concentration of relevant molecular species as a function of time and/or space<sup>115–117</sup>; correlation and information-theoretical approaches, producing genome-wide context-specific maps of functional molecular relationships<sup>59,118,119</sup>; and integrative approaches, leveraging partially independent clues for regulatory network reconstruction<sup>39,120</sup>.


Although all these methods have been benchmarked on their ability to reconstruct known topologies<sup>121</sup>, the dialogue for the reverse engineering assessments and methods (DREAM), a conference dedicated to evaluating systems biology algorithms based on double-blind benchmarking criteria<sup>122,123</sup>, has shown that performance depends strongly on the data type and target network size. For instance, kinetic models have the highest level of granularity but their large number of parameters limits their applicability to small networks with only a handful of molecules<sup>116</sup>. Optimization-based approaches, including Bayesian networks, provide an optimal choice for small to middle-sized networks<sup>70</sup>. Correlation and information-theoretical methods are best suited to genome-wide regulatory network inference<sup>109</sup> but provide only qualitative interaction models.

Genome-wide networks can also be obtained by integrating experimental data from the literature or high-throughput experiments, but these models generally combine evidence from multiple, often non-physiological cellular contexts that may lack tumour-context specificity.

Information theory-based approaches have been used to produce genome-wide representations of yeast regulatory networks<sup>124,125</sup> and context-specific models of mammalian cell regulation<sup>39,59,126</sup>. However, regardless of the level of complexity, the regulatory models they produce are context specific<sup>126,127</sup>.

Different cellular lineages express different genes and even different protein isoforms, as expression products of alternative splice variants. Crucially, differential availability of scaffolding proteins or adaptors can profoundly reshape (rewire) the topology of protein–protein interaction networks<sup>128,129</sup>, and differential availability of cofactors and chromatin state between cells can lead to strong rewiring of transcriptional networks<sup>58,66,78</sup>. Thus, reliance on context-free, literature-based pathway models<sup>130</sup>, arising from the biologist’s desire to linearize and visualize the cell’s regulatory logic, can be misleading. The need for context-specific models is highlighted in parts **a** and **b** of the figure, where we show that the ability of Virtual Inference of Protein Activity by Enriched Regulon Analysis (VIPER) to correctly assess the activity changes of proteins encoded by silenced genes in lymphoma, glioma and breast carcinoma cells depends strongly on using the correct tissue-matched interactome<sup>38</sup>. Moreover, as also discussed in REF. 38, regulatory models based on ChIP enrichment analysis (ChEA)<sup>113</sup> and Encyclopedia of DNA Elements (ENCODE)<sup>60</sup> protein–DNA interaction data, as well as canonical pathways from the Ingenuity Pathway Analysis platform<sup>72</sup> failed to properly detect differential activity of most proteins (see for example, BCL-6, the regulon of

which is highly context specific) except forkhead box M1 (FOXM1), the regulatory programme of which is highly conserved across all tested tissues owing to its role in cell cycle regulation<sup>131</sup> (part **c** of the figure). ARACNe, Algorithm for the Accurate Reconstruction of Cellular Networks; BCELL, B cell lymphoma; BLCA, bladder urothelial cancer; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colorectal adenocarcinoma; ESCA, oesophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukaemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MEF2B, myocyte enhancer factor 2B; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; PTTG1, pituitary tumour-transforming 1; READ, rectal adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; STAT3, signal transducer and activator of transcription 3; TGCT, testicular germ cell tumour; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial cancer; XBP1, X-box binding protein 1.



**The tumour checkpoint of mesenchymal glioblastoma.** Glioblastoma (GBM) presents with multiple molecular subtypes. Despite classification differences<sup>79,80</sup>, there is global consensus that the mesenchymal subtype (MES-GBM) is associated with the poorest prognosis<sup>7,79</sup>. The first reported example of systematic MR analysis and validation elucidated a MES-GBM-specific tumour checkpoint, including six MR proteins —  $\beta$  and  $\delta$  isoforms of CCAAT/enhancer-binding protein (CEBP), signal transducer and activator of transcription 3 (STAT3), class E basic helix–loop–helix protein 40 (BHLHE40; also known as BHLHB2), runt-related transcription factor 1 (RUNX1) and Fos-related antigen 2 (FOSL2). These were validated as positive mechanistic regulators of >74% of MES-GBM signature genes. A seventh MR — zinc finger protein 238 (ZNF238) — was identified as an aberrantly inactivated MR and was independently confirmed as a fibroblast-to-neuron reprogramming factor<sup>81</sup>. Surprisingly, these MRs were not among the 500 most differentially expressed genes and only one of them (CEBPD) was later found to be focally amplified in 30% of MES-GBMs<sup>7</sup>.

Further analysis revealed a highly modular architecture, with CEBP $\beta$ , CEBP $\delta$  and STAT3 regulating each other as well as the other MRs and jointly regulating the MES-GBM gene expression signature through a large number of feed-forward loops (FIG. 5). Although only ~6% of CEBP $\beta$  and STAT3 target genes were mesenchymal, based on Gene Ontology, 36% of targets regulated by both CEBP $\beta$  and STAT3 were mesenchymal, suggesting synergistic interaction<sup>39</sup>. Indeed, ectopic co-expression of CEBP $\beta$  and STAT3 (but not of either one in isolation) was sufficient to induce reprogramming of neural stem cells along an aberrant mesenchymal lineage. Conversely, shRNA-mediated silencing of both genes (but not of either one in isolation) was sufficient to abrogate viability of MES-GBM tumours in mouse xenograft models. Pure feed-through regulation, for example, as implemented by an 'AND' or 'OR' logic, cannot explain CEBP $\beta$  and STAT3 dependency for both module activation and inactivation. As was later confirmed<sup>7</sup>, this implies existence of an autoregulatory logic implemented by feedback loops.

Notably, cancer states represent the superposition of multiple independent hallmarks<sup>82</sup>. This requires the potential coexistence of multiple tumour checkpoints, each one regulating or buffering one or

more of these programmes. In glioma, for instance, MES-GBM MRs were shown to regulate migration, invasion and angiogenesis but not proliferation or apoptosis. As a result, although still crucially necessary for tumour state maintenance and *in vivo* tumour viability, their co-activation is not sufficient for tumorigenesis. This is easily explained: tumour checkpoint analysis identifies MRs that are necessary and sufficient to implement a specific differential phenotype, as captured by the corresponding differential gene expression signature. Thus, the analysis will miss MRs of programmes that are unchanged in the transition. The differential expression signature used in the GBM study represents the difference between its mesenchymal and its proneural subtypes, which are distinct, yet both tumour-associated states. Hence, tumorigenesis programmes are essentially removed from the analysis. This is important, because the specific selection of cellular states that define the gene expression signature ultimately determines the role of identified MR proteins, and selection of inappropriate signatures can drastically affect the outcome of MR studies.

This study highlighted six hallmark properties of tumour checkpoints that were also confirmed in follow-up studies, both in cancer<sup>7,9,29,30,83</sup> and in other phenotypes<sup>39,53,55–57</sup>. Specifically, MR proteins form highly modular and tightly regulated structures (tumour or disease checkpoint modules) (FIG. 5); implement stable, redundant control of downstream cancer programmes through multiple feed-forward loops; regulate each other, both directly and via autoregulatory loops, thus increasing tumour checkpoint stability; are highly enriched in tumour-specific dependencies, including essential MRs and/or synthetic lethal MR pairs; are differentially active but not generally differentially expressed; and only rarely harbour genetic alterations. Among these, the first four points also represent crucial hallmarks of homeostatic control. Indeed, because of their inherent stability, tumour checkpoint collapse generally requires co-inhibition of two or more proteins (that is, synthetic lethality). This decreases the chances of detecting key synthetic lethal MRs, such as STAT3 and CEBP $\beta$  in MES-GBM, by pooled RNA interference (RNAi) or CRISPR-based functional screens that target individual genes.

**Cross-species MR analysis.** The hallmarks of a tumour checkpoint oncotope were further recapitulated by cross-species

analysis of aggressive prostate cancer checkpoint MRs, using data from both human biopsies and genetically engineered mouse models<sup>9</sup>. Gene expression profiles for interactome generation were obtained from a high-quality human cohort, for which both expression and outcome data were available<sup>84</sup>, and from prostate tissue harvested from 13 distinct genetically engineered mouse models (including wild-type controls) following *in vivo* treatment with 14 compounds targeting prostate-relevant pathways (including dimethylsulfoxide (DMSO) as control medium). A gene expression signature of aggressive human prostate cancer was obtained by comparison of gene expression in tumours with high Gleason score with confirmed biochemical recurrence within 3 years, against gene expression of tumours with low Gleason score with no biochemical recurrence. Equivalent signatures were obtained from four distinct genetically engineered mouse models associated with aggressive disease (harbouring *Myc*, *Trp53*, *Braf* and *Kras* mutations). Strikingly, 8 of the top 20 human MRs identified by the analysis were also identified from each of the four mouse model-derived gene expression signatures. This included the only predicted synergistic MR pair — forkhead box M1 (*FOXM1*) and centromere protein F (*CENPF*) — the universal synthetic lethality of which in aggressive prostate cancer was validated *in vitro* and *in vivo*. Synthetic lethality of this MR pair in malignant prostate cancer emerged as virtually independent of both genetic and organism background, thus further supporting the hypothesis that checkpoint MRs uncouple tumour phenotypes from upstream genetics. These results were further confirmed in a cohort of >900 patients, for which tissue microarrays (TMAs) were available. Although almost no patients with double negative immunohistochemistry (IHC) staining for FOXM1 and CENPF at diagnosis died of the disease for up to 20 years from diagnosis, those with double positive FOXM1 and CENPF IHC constituted 90% of prostate cancer-associated deaths, suggesting that co-activation of FOXM1 and CENPF is necessary and sufficient to implement the most aggressive form of these tumours that are associated with poor prognosis.

#### **Integration with functional screens.**

MR analysis may also be used effectively to mitigate discovery of idiosyncratic dependencies from pooled RNAi screens. For instance, isogenic MCF-10A breast





trastuzumab-resistant patient-derived xenografts (PDXs)<sup>29</sup>, providing the rationale for a phase I/II clinical trial<sup>85</sup>.

**The oncotecture of tumour relapse**

Progression to drug-resistant disease represents perhaps the most substantial challenge in cancer treatment. Indeed,

despite initial and often striking responses to therapy, most cancer patients will relapse with poor prognosis tumours that no longer respond to chemotherapy or targeted therapy. Thus, there is a pressing need for novel methodologies to identify therapeutic targets that either predict relapse or rescue drug sensitivity in relapsed

tumours. For example, subclonal expansion of drug-resistant clones, for instance, is a well-studied relapse mechanism. Indeed, because of the extensive genomic diversity of individual tumour cells, it is only a matter of time before one or more drug-resistant subclones emerges with bypass or alternative mutations<sup>86,87</sup>. However, many additional adaptive mechanisms exist that modulate drug sensitivity epigenetically, including transient<sup>88</sup> or stable<sup>89</sup> epigenetic reprogramming, as well as by triggering mechanisms of resistance that are purely regulatory in nature<sup>29</sup> — for instance, from activation of autocrine feedback loops, as discussed above. In each case, drug resistance is associated with a stable and molecularly distinct tumour cell state. It is thus reasonable to consider whether these states might also be implemented and maintained by aberrant activity of specific tumour checkpoints and whether pharmacological targeting of the corresponding MRs might rescue sensitivity or even prevent relapse.

**MRs of glucocorticoid resistance in T cell acute lymphoblastic leukaemia.**

The tumour checkpoint–MR conceptual framework was applied to the study of glucocorticoid (GC) resistance in T cell acute lymphoblastic leukaemia (T-ALL). Despite their highly heterogeneous genetic determinants<sup>90</sup>, first-line therapy for these tumours universally relies on a class of high-affinity, cognate binding agonists of the GC receptor nuclear receptor subfamily 3 group C member 1 (NR3C1). Although never mutated in leukaemias, NR3C1 regulates apoptosis by direct transcriptional activation of the pro-apoptotic factor BCL-2-like protein 11 (BCL2L11; also known as BIM). Remarkably, 70% of GC-treated T-ALLs undergo long-term remission. However, 30% of them relapse within weeks with GC-resistant disease and poor prognosis.

To identify MRs of GC-therapy resistance, we analysed gene expression signatures collected at diagnosis (that is, before treatment) from 22 patients with GC-resistant disease and 10 patients with GC-sensitive disease. Differential gene expression of resistant versus sensitive tumours was then used for MR analysis, using a T-ALL-specific interactome. The analysis identified nine MR proteins, three of which — serine/threonine protein phosphatase 2A 56 kDa regulatory subunit-δ (PPP2R5δ), galactosylgalactosylxylosyl-protein 3-β-glucuronosyltransferase 3

**Glossary**

**Bayesian networks**

Probabilistic models representing the probabilities and conditional probabilities of variables representing nodes in a directed acyclic graph, that is, a type of network with nodes connected by directionally defined edges, usually represented as arrows, with no circular paths (cycles). This model is often used to determine the probability of an unknown event corresponding to one node as a function of the probability of other known events in the network.

**Dystatic**

Describes the aberrant processes responsible for implementing and maintaining a stable disease state, independent of most genetic, epigenetic and environmental perturbations.

**Feed-forward loops**

Regulatory structures in which a gene product (A) regulates a second gene product (B) and, together, A and B regulate one or more target gene products. These structures constitute a directed acyclic graph.

**Homeostasis**

The set of regulatory processes that ensures the overall stability of a system state, independent of endogenous and exogenous variables.

**Interactomes**

Sets of molecular interactions that constitute the regulatory logic of cells representative of a specific tissue and organism.

**Isobologram**

A two-dimensional map representing the viability of a cell following perturbation with a combination of two compounds. Each isobologram axis represents the concentration of an individual compound. This diagram is used to quantitatively assess whether the effect of the compound pair is additive, synergistic or antagonistic. This assessment is based on whether the isoboles (that is, curves in the diagram representing isopotency of the combination) are linear or nonlinear. Linear isoboles indicate additive behaviour, whereas nonlinear isoboles indicate synergistic (supra-additive) or antagonistic (sub-additive) behaviour.

**Master regulator**

(MR). Type of protein participating in a modular regulatory structure (that is, tumour checkpoint), the aberrant activity of which is both necessary and sufficient for tumour cell state implementation and maintenance and which directly controls the transcriptional state of a tumour cell.

**Multiple hypothesis testing**

When a test is repeated multiple times — for instance, a pair of dice are thrown multiple times — the probability of an outcome must be adjusted. This is a common problem in genetics, for example, where a large number of loci are

tested to assess whether they are mutated in a cancer cohort, thus increasing the overall probability that any one of them may be mutated by chance.

**Oncogene addiction hypothesis**

The hypothesis that tumours become dependent on the aberrant activity of proteins encoded by mutated oncogenes and that pharmacological inhibition of these proteins will cause tumour demise.

**Oncotecture**

The regulatory architecture responsible for implementing tumour dystasis, comprising one or more tumour checkpoints that are responsible for integrating the effect of multiple mutations and aberrant signals in their upstream pathways to implement a conserved repertoire of downstream transcriptional programmes that are necessary and sufficient for tumour phenotype presentation.

**Regulatory logic**

The full complement of transcriptional, post-transcriptional and post-translational molecular interactions that determine cell behaviour.

**Regulons**

The full complement of transcriptional targets that are regulated by a protein. These can include either direct physical targets, for transcription factors and cofactors, or indirect targets for signal transduction.

**Reverse engineering**

Systematic dissection of the molecular interactions that comprise the regulatory logic of the cell.

**Sample barcoding**

A technique enabling incorporation of a predefined nucleic acid sequence (barcode) to tag either DNA or RNA molecules coming from a common sample so that they can be sequenced as a pool while retaining the ability to deconvolute which sample they came from.

**Silhouette score**

A measure, from –1 to 1, of how similar an object is to its own cluster compared with the closest other cluster.

**Synthetic lethal**

An interaction between two genes in which knockout of either gene in isolation has no (or minimal) negative impact on cell viability whereas knockout of both genes is lethal.

**Tissue microarrays**

(TMAs). Paraffin blocks in which up to 1,000 separate tissue cores are embedded in a grid to support multiplexed immunohistological analyses.

**Tumour checkpoint**

A small, autoregulated module comprising one or more master regulator (MR) proteins, the concerted activity of which is both necessary and sufficient for the implementation and maintenance of a tumour cell state.

(B3GAT3) and AKT1 — rescued sensitivity to dexamethasone (a NR3C1 agonist), when silenced in GC-resistant cells. AKT1-mediated NR3C1 phosphorylation at Ser134, in particular, prevented NR3C1 nuclear translocation and transcriptional activation of *BCL2L1* (REF. 30). Consistently, treatment with MK2006 (an AKT1 inhibitor) rescued dexamethasone sensitivity *in vitro* and *in vivo*, including in PDXs transplanted with leukaemic cells from patients with GC-resistant disease<sup>30</sup>. AKT1 thus emerged as a key tumour checkpoint MR downstream of recurrent T-ALL mutations, including in PI3K and PTEN and further mediating resistance by inducing mTOR-mediated increase in the expression of the *MCL1* antiapoptotic gene<sup>91</sup>.

A key aspect of this study is that it confirmed the ability to extend MR analyses to signal transduction proteins, based on identification of their least-indirectly regulated transcriptional targets, as also shown in REF. 38.

### MR-based model fidelity assessment

The above-discussed studies highlight a key property of tumour checkpoints, specifically their conservation, independent of specific driver mutation patterns and even across different organisms. This is important because, compared with their human counterparts, driver mutations and microenvironment signals in cell lines and preclinical models are highly idiosyncratic. This suggests that tumour checkpoint conservation, as objectively assessed by MR enrichment analysis, may support more effective use of these models as high-fidelity, predictive experimental surrogates. This would be quite valuable, as validation in cell lines and in preclinical models — including genetically engineered mouse models and xenografts — is considered mandatory on the path to clinical translation<sup>92</sup>.

More specifically, these results support the idea of a human-to-mouse-to-human (H2M2H) methodology<sup>31,93</sup>, in which preclinical models are optimally matched to human tumours based on the statistical significance of their tumour checkpoint MR overlap. This would increase the probability of results from preclinical studies using these models being relevant to human disease. As all the steps required for MR inference — including network reverse engineering and MR analysis — rely exclusively on patient-derived tissue, MR identification is completely free of bias from using cell line and model organisms. This limits the use of MR-matched models only to validation

assays rather than to discovery assays. By contrast, classic drug discovery methods screen for targets and inhibitors using cell lines or animal models, the relevance of which to human disease is questionable, not quantitatively assessed and often subjective, thus reducing the probabilities that results may translate to clinical studies.

### Genetic determinants of MR activity

Similar to p50-RELA in ABC-DLBCL, lack of differential MR expression or mutations suggests that aberrant activity of MES-GBM MRs (that is, CEBP $\beta$ , CEBP $\delta$  and STAT3) may result from genomic alteration in their upstream pathways. Although several algorithms can detect association of genomic alterations with differential gene expression (genetical-genomics)<sup>94</sup> or perform network-based clustering of genomic alterations<sup>95</sup> (see REF. 48 for a review), there are no methods for the genome-wide, tumour-specific exploration of alterations in signalling pathways upstream of candidate MR proteins.

The Driver-gene Inference by Genetical-Genomics and Information Theory (DIGGIT) pipeline<sup>7</sup>, available from Bioconductor<sup>96</sup>, was developed precisely to address this challenge. DIGGIT relies on the Modulator Inference by Network Dynamics (MINDy) algorithm<sup>66</sup> to systematically identify all candidate modulators of one or more MR proteins in their upstream pathways. One may argue that extensive feedback control — including via paracrine interactions with the stroma — may dramatically inflate the number of upstream pathway proteins. Yet, MINDy-based inference reveals only a relatively small number (10–100) of statistically significant modulators of any candidate MR, most of which are experimentally confirmed, thus dramatically reducing the potential search space for mutations that may affect MR activity<sup>7,66</sup>.

For instance, among the multitude of genes of which the expression was affected by recurrent copy number alterations (CNAs) in the MES-GBM subtype, MINDy inferred that only 92 genes were either MRs or upstream MR-activity modulators. Of these, only 21 showed significant association between their corresponding CNA and the activity of MES-GBM MRs. Conditional association analysis of these 21 genes revealed only two statistically independent alterations, including amplification of *CEBPD*, itself an MR, in ~30% of MES-GBM tumours, and homozygous deletion of kelch-like family member 9 (*KLHL9*) —

a putative adaptor protein in the cullin 3 (CUL3) ubiquitin ligase complex — in ~50% of the MES-GBM tumours. Experimental validation and independent cohort analysis confirmed that competent KLHL9 activity is crucial for ubiquitin-dependent proteasomal degradation of CEBP $\beta$  and CEBP $\delta$ , as well as for STAT3 dephosphorylation. Consistent with this result, IHC analysis of *KLHL9*<sup>-/-</sup> tumours showed significant increase in CEBP $\beta$  and CEBP $\delta$  protein abundance, and their *in vivo* viability was dramatically reduced by ectopic KLHL9 expression<sup>7</sup>. Similar analyses were also carried out in breast cancer<sup>7</sup> using different MRs, inferred at the individual sample level.

These results define two distinct protein classes: the first class includes MR proteins (for example, CEBP $\beta$  and STAT3), co-activation of which is strictly necessary and sufficient for tumour phenotype presentation. The second class includes MR modulators, dysregulation of which by mutations or aberrant signals induces aberrant MR activity (for example, KLHL9 and CEBP $\delta$ ). Proteins in the latter class, which includes most of the established oncogenes and tumour suppressors, may be sufficient but not necessary for tumour checkpoint activity and phenotype presentation and are thus not predicted to be MRs by MARINa. For instance, *KLHL9* is deleted in only ~50% of MES-GBM samples, suggesting that this event is not strictly required for MES-GBM subtype implementation. In rare cases in which aberrant MR activity results from genetic alterations at its locus (for example, *CEBPD*), these two classes may overlap.

When combined with identification of mutations in pathways upstream of NF- $\kappa$ B in DLBCL and with conservation of prostate cancer MRs in four different genetically engineered mouse models with distinct driver mutations, these studies further confirm that tumour checkpoints represent the cellular logic that is responsible for integrating the effect of large and heterogeneous genomic alteration repertoires into virtually indistinguishable tumour states. This also supports the role of tumour checkpoint MRs as highly conserved, mechanistic therapeutic targets and biomarkers. Indeed, based on the proposed oncotecture model, tumour checkpoints emerge as the regulatory pillars of tumour dystasis and thus, potentially, as the universal Achilles heels of cancer. Consistent with this observation, these and other studies have shown that collapse of tumour checkpoint activity — as induced from genetic<sup>9,10</sup> or pharmacological<sup>11,29–31</sup>



inhibition of individual MRs or MR pairs — induces crucial loss of tumour state and abrogation of tumour viability or rescue of drug sensitivity, *in vitro* and *in vivo*. This has important consequences in terms of the potential use of tumour checkpoints as more universal (that is, mutation independent) tumour vulnerabilities that are intrinsically less susceptible to typical relapse mechanisms. Indeed, whenever relapse is induced by alternative or bypass mutations or by epigenetic mechanisms that act upstream of the same tumour checkpoint, its direct targeting should mitigate relapse<sup>29,30</sup>.

### Extending oncogene dependency

Tumorigenesis arises from the aberrant activity of multiple gene products working in concert. Activating mutations represent a highly reproducible predictor of aberrant oncogene activity and can thus be used to pinpoint valuable pharmacological targets, as proposed by the oncogene addiction hypothesis<sup>97</sup>. Indeed, following the clinical success of imatinib — an inhibitor of the BCR–ABL fusion protein in chronic myelogenous leukaemia (CML)<sup>98</sup> — oncogene addiction has become a *de facto* paradigm for targeted therapy in precision medicine.

Yet, direct mutations are only one of many ways to induce aberrant protein activity, and there are innumerable alternatives to achieve a virtually identical objective. These include mutation in upstream modulators<sup>7,8</sup>, cognate binding partners<sup>99</sup> and autoregulatory loops<sup>29</sup>, among others<sup>8,100</sup>. Even assuming a single functional mutation per gene product, the activity of oncoproteins regulated by  $\geq 100$  other gene products, such as MYC<sup>66</sup>, could be dysregulated by any combination of mutated oncogenes out of the 100 possible ones. This accounts for more than  $10^{30}$  distinct genomic alteration patterns, as computed by the binomial coefficient formula. Even if most of them failed to induce pathogenic activity levels, it is still reasonable to expect the existence of a large number of distinct, non-recurrent yet tumorigenic mutational patterns. For instance, PTEN activity in glioma was shown to be dysregulated by multiple deletions of any among 13 frequently deleted genes<sup>61</sup>, each individually affecting PTEN expression by less than 20%. Unfortunately, owing to multiple hypothesis testing, evaluating the statistical significance of such polygenic patterns would require prohibitive cohort sizes.

Two important observations emerge from these considerations. First, despite successful identification of key recurrent,

high-penetrance driver mutations — such as BCR–ABL translocation events in CML<sup>98</sup>, KRAS mutations in up to 90% of pancreatic ductal adenocarcinomas<sup>101</sup>, BRAF mutations in almost 50% of melanomas<sup>102</sup> and ERBB2 amplification in 20–30% of breast ductal adenocarcinomas<sup>103</sup> — we are starting to run out of such low-hanging fruits. It is thus reasonable to expect a long tail of more complex (additive or epistatic) genomic alteration patterns that will be increasingly less recurrent and thus harder to dissect via statistical inference methods. Among other things, this suggests that existing targeted inhibitors could be used more effectively in the clinics if oncoprotein activity could be assessed directly, rather than indirectly based on mutations (BOX 3).

Indeed, VIPER-inferred oncoprotein activity systematically outperformed activating mutations in predicting sensitivity to targeted inhibitors by an order of magnitude in statistical significance on average. For instance, the *P* value of erlotinib sensitivity prediction in 80 Cancer Cell Line Encyclopedia (CCLE) lung cancer cell lines is  $P = 3.3 \times 10^{-2}$  when the mutational status of epidermal growth factor receptor (EGFR; the target of erlotinib) is used, and  $P = 3.2 \times 10^{-3}$  when VIPER-inferred EGFR activity is used (BOX 3). This suggests that the oncogene addiction paradigm could be complemented and extended by direct measurement or inference of protein activity.

### Pharmacological MR targeting

Elucidation of tumour checkpoint MRs and MR pairs that represent either individual (essential) or synergistic (synthetic lethal) dependencies, independent of the associated genomic alterations, provides a largely novel and more universal repertoire of targets for pharmacological intervention. However, many of the MRs and MR pairs that determine tumour checkpoint activity are transcription factors, which are considered challenging or even undruggable targets. As a result, even if MR proteins were effectively validated as valuable therapeutic targets, development of small molecule inhibitors that modulate their activity may require an entirely novel chemistry.

Yet, the current repertoire of FDA-approved drugs includes ~2,000 compounds, with an additional ~400 oncology-related investigational compounds in late-stage (phase II/III) clinical studies. Many of these have mechanisms of action (MOAs) that are only partially elucidated and may thus represent unexpected, tumour-specific inhibitors of MR proteins. Specifically, we

have shown that systematic perturbational assays, either *in vitro*<sup>104,105</sup> or *in vivo*<sup>31</sup>, using tumour-representative cell lines or mouse models, can help to prioritize targeted inhibitors optimally suited to the abrogation of tumour checkpoint MR activity, including MRs that are usually thought to be undruggable<sup>11,31</sup>. The rationale for these studies is that, although crucial tumour dependencies may be substantially different in the human tumour context versus *in vitro* and *in vivo* models, drug MOA is generally reasonably well conserved. Indeed, pharmacological compound MOA is typically elucidated *in vitro*. Of course, compounds that modulate the immune system — such as the recent repertoire of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1; also known as PDCD1)–PD1 ligand 1 (PDL1; also known as CD274) inhibitors — would have to be investigated either in immune system-related cell lines or in transgenic mouse models with an intact immune system.

The ability of a compound to inhibit specific MR proteins is directly reflected in the inversion of expression of its regulon. As a result, the same regulons used to identify tumour MRs represent ideal quantitative reporter assays to prioritize their candidate inhibitors, specifically by measuring enrichment of their regulons in genes that are differentially expressed following compound perturbation, for example, as discussed in REF. 38.

To validate this approach, we performed systematic perturbation of human DLBCL cells, including OCI-LY7 cells using 14 compounds and then of OCI-LY3, OCI-LY7 and U-293 cells using 92 FDA-approved compounds, at different time points and at multiple concentrations. Gene expression profiles from these assays were then used to systematically elucidate the MOA of the compounds<sup>105</sup> and their ability to target disease-specific MR genes, either individually or in combination (synergistically)<sup>104</sup>. This successfully demonstrated that interrogation of gene regulatory networks reconstructed *de novo* in context-specific tumours can help to elucidate compound MOA and identify compounds and compound combinations that target the activity of DLBCL subtype-specific MR proteins, thus reducing tumour viability. Surprisingly, for instance, at a low false discovery rate (FDR = 8%), >60% of predicted synergistic compound combinations were experimentally confirmed by isobologram analysis<sup>104,106</sup>. These data were valuable for the identification of drugs and drug combinations that abrogate



viability of aggressive follicular lymphoma cells following transformation to DLBCL<sup>11</sup>, by targeting experimentally validated MRs and synergistic MR pairs. *In vivo*, we recently showed that a similar approach could identify drug combinations that abrogate FOXM1 and CENPF activity in multiple transgenic mouse models of prostate cancer, in which these were validated as synergistic MR pairs<sup>31</sup>. The most statistically significant drug combination identified by the analysis produced a 9-fold decrease in tumour volume *in vivo*, in tumour xenografts that failed to respond to conventional therapy.

A key value of network-based approaches is that MR inference can tolerate very low RNA sequencing depths, down to 500,000 reads, with virtually no decrease in the accuracy of MR activity prediction (Pearson's correlation coefficient  $\geq 0.95$ )<sup>38</sup>. This suggests that with appropriate sample barcoding techniques for the creation of pooled RNA-seq libraries, the cost of individual profiles from compound perturbations

could be dramatically reduced without loss of accuracy. This would enable cost-effective screening of large compound libraries, including, for example, FDA-approved and late-stage investigational compounds.

**Conclusions**


Despite considerable progress in integrative and systems biology approaches, computational assessment of gene–function relationships is still mostly carried out one gene at a time. The use of pathways is generally limited to visual diagrams that poorly represent their context-specific nature and their true connectivity. This is particularly ineffective in studying complex polygenic dependencies, including synthetic lethal interactions that cannot be gleaned on an individual gene basis and yet are crucially relevant for the systematic development of combination therapies.

Recent progress in the systematic and context-specific mapping of regulatory and signalling interactions supports novel

approaches that explore the mechanistic architecture of disease state maintenance downstream of the genes associated with its aetiology. In this Opinion article, we have explored a recently proposed regulatory architecture in which MR proteins implement tightly autoregulated tumour checkpoint modules that are responsible for the stability of cancer states, independent of specific genetic mutations, using mechanisms reminiscent of physiological homeostasis. Such dystatic regulatory oncotecture may provide a conceptual framework to help unravel the complexity and profound heterogeneity of cancer genetics. For instance, it may provide a tractable set of constraints to interpret the evolutionary selection of additional mutational events that may confer selective advantage to the corresponding cancer cell subclones, by affecting upstream modulators of tumour checkpoint MRs that control proliferative programmes.

**Box 3 | Protein activity inference complements analysis of genetic alterations in assessing aberrant oncoprotein activity**

Cancer is driven by the aberrant activity of proteins (oncoproteins) working in concert to regulate tumour cell states. Indeed, pharmacological inhibition of aberrantly activated oncoproteins can elicit oncogene dependency, which represents the basis for the oncogene addiction paradigm and the foundation of current efforts in precision cancer medicine<sup>97</sup>. Activating genetic alterations have thus emerged as an important rationale for the identification of therapeutic targets in individual patients. Yet, activating mutations represent only one of many possible ways of dysregulating protein activity, which may also result from a vast complement of genetic and epigenetic events in cognate binding partners<sup>99</sup> and upstream regulators<sup>7</sup>. For instance, lung adenocarcinoma (LUAD) cells with activating mutations in a specific oncogene (for example, the epidermal growth factor receptor (EGFR)) may be sensitive to the corresponding targeted inhibitor (erlotinib). Yet cells lacking these mutations may also present equivalent sensitivity<sup>28,132</sup> (see part **a** of the figure, which shows 80 Cancer Cell Line Encyclopedia (CCLE) lung cancer cell lines ranked by their sensitivity to erlotinib — the expanded inset shows the 25 cell lines with the highest sensitivity to erlotinib). Conversely, owing to homeostatic feedback mechanisms and epigenetic allele silencing, activating mutations may not guarantee aberrant oncoprotein activity. As a result, the direct or inferred assessment of protein activity may constitute a valuable complement to genetic analysis for prioritization of targeted therapy, especially as a large proportion of cancer patients present no actionable oncogene mutations. Indeed, samples from The Cancer Genome Atlas (TCGA) LUAD cohort show striking enrichment of activating EGFR mutations in samples with the highest Virtual Inference of Protein Activity by Enriched Regulon Analysis (VIPER)-inferred EGFR activity (part **b** of the figure — the expanded inset shows samples with the highest activity). However, many samples showed comparably high activity but no activating mutations, suggesting that they may also respond to targeted EGFR inhibitors, as shown for the cell lines. AUC, area under the curve; GSEA, gene set enrichment analysis; NES, normalized expression score.



There are several crucial unaddressed issues implied by such a tumour-independent oncotecture. These include whether tumour heterogeneity supports the plastic coexistence of distinct cancer cell states in the same tumour, which may require pharmacological targeting of multiple distinct tumour checkpoint MRs, for example, using alternating treatment schedules. For instance, in glioma, mesenchymal and proneural subtype cells coexist plastically in the same tumour<sup>107</sup>, even though these states have been shown to be regulated by orthogonal tumour checkpoints<sup>10</sup>. In addition, it is unclear how many distinct tumour checkpoints may coexist even in the same tumour cell. For instance, tumour checkpoints associated with proliferation and epithelial-to-mesenchymal transition are probably distinct, given the serial nature of the cancer initiation and progression steps associated with their activation. It is thus possible that a relatively small number of molecularly distinct tumour checkpoints exist and that their activation in distinct tumour subtypes depends on distinct genetic alteration patterns. Combinatorial superposition of two or more of these mechanisms in each individual tumour may thus explain the large variety of reported tumour subtypes and of associated clinical phenotypes and drug sensitivities.

Ultimately, we propose that tumour checkpoint and MRs may be leveraged to simultaneously identify crucial tumour dependencies, as well as the specific drugs and drug combinations that are optimally suited to inducing their collapse, on the basis of an individual sample and even an individual cell. This would have obvious application to complementing oncogene addiction and immune checkpoint paradigms in precision medicine.

Andrea Califano is at the Department of Systems Biology, Columbia University, and the Departments of Biomedical Informatics, Biochemistry and Molecular Biophysics, JP Sulzberger Columbia Genome Center, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA.

Mariano J. Alvarez is at DarwinHealth, Inc., 3960 Broadway, Suite 540, New York, New York 10032, USA.

Correspondence to A.C. [andrea.califano@columbia.edu](mailto:andrea.califano@columbia.edu)  
doi:10.1038/nrc.2016.124  
Published online 15 Dec 2016

1. Hoadley, K. A. *et al.* Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell* **158**, 929–944 (2014).
2. Shah, S. P. *et al.* The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* **486**, 395–399 (2012).
3. Verhaak, R. G. *et al.* Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma

- characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* **17**, 98–110 (2010).
4. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346–352 (2012).
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70 (2012).
6. Oakman, C., Santarpià, L. & Di Leo, A. Breast cancer assessment tools and optimizing adjuvant therapy. *Nat. Rev. Clin. Oncol.* **7**, 725–732 (2010).
7. Chen, J. C. *et al.* Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. *Cell* **159**, 402–414 (2014).
8. Compagno, M. *et al.* Mutations of multiple genes cause deregulation of NF- $\kappa$ B in diffuse large B-cell lymphoma. *Nature* **459**, 717–721 (2009).
9. Aytes, A. *et al.* Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. *Cancer Cell* **25**, 638–651 (2014).
10. Carro, M. S. *et al.* The transcriptional network for mesenchymal transformation of brain tumours. *Nature* **463**, 318–325 (2010).
11. Bisikirska, B. *et al.* Elucidation and pharmacological targeting of novel molecular drivers of follicular lymphoma progression. *Cancer Res.* **76**, 664–674 (2016).
12. Yang, J. *et al.* Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* **117**, 927–939 (2004).
13. Nambu, J. R., Lewis, J. O., Wharton, K. A. Jr & Crews, S. T. The *Drosophila* single-minded gene encodes a helix–loop–helix protein that acts as a master regulator of CNS midline development. *Cell* **67**, 1157–1167 (1991).
14. Resnick, M. A., Tomso, D., Inga, A., Menendez, D. & Bell, D. Functional diversity in the gene network controlled by the master regulator p53 in humans. *Cell Cycle* **4**, 1026–1029 (2005).
15. Klapper, L. N., Kirschbaum, M. H., Sela, M. & Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. *Adv. Cancer Res.* **77**, 25–79 (2000).
16. Perou, C. M. *et al.* Molecular portraits of human breast tumours. *Nature* **406**, 747–752 (2000).
17. Dalla-Favera, R. *et al.* Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc. Natl Acad. Sci. USA* **79**, 7824–7827 (1982).
18. Klein, U. *et al.* Transcriptional analysis of the B cell germinal center reaction. *Proc. Natl Acad. Sci. USA* **100**, 2639–2644 (2003).
19. Akavia, U. D. *et al.* An integrated approach to uncover drivers of cancer. *Cell* **143**, 1005–1017 (2010).
20. Gu, J. *et al.* Gene module based regulator inference identifying miR-139 as a tumor suppressor in colorectal cancer. *Mol. Biosyst.* **10**, 3249–3254 (2014).
21. Ergun, A., Lawrence, C. A., Kohanski, M. A., Brennan, T. A. & Collins, J. J. A network biology approach to prostate cancer. *Mol. Syst. Biol.* **3**, 82 (2007).
22. Cannon, W. B. Organization for physiological homeostasis. *Physiol. Rev.* **9**, 399–431 (1929).
23. Waddington, C. H. Canalization of development and genetic assimilation of acquired characters. *Nature* **183**, 1654–1655 (1959).
24. Waddington, C. H. Genetic assimilation. *Adv. Genet.* **10**, 257–293 (1961).
25. Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF- $\beta$  in homeostasis and cancer. *Nat. Rev. Cancer* **3**, 807–821 (2003).
26. Carter, S. B. Tissue homeostasis and the biological basis of cancer. *Nature* **220**, 970–974 (1968).
27. Young, S. R. *et al.* Establishment and serial passage of cell cultures derived from LuCaP xenografts. *Prostate* **73**, 1251–1262 (2013).
28. Barretina, J. *et al.* The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603–607 (2012).
29. Rodríguez-Barrueco, R. *et al.* Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR<sup>+</sup>/HER2<sup>+</sup> breast cancers. *Genes Dev.* **29**, 1631–1648 (2015).
30. Piovani, E. *et al.* Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. *Cancer Cell* **24**, 766–776 (2013).

31. Mitrofanova, A., Aytes, A., Shen, C., Abate-Shen, C. & Califano, A. A systems biology approach to predict drug response for human prostate cancer based on *in vivo* preclinical analyses of mouse models. *Cell Rep.* **12**, 1–12 (2015).
32. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. *J. Exp. Med.* **194**, 1861–1874 (2001).
33. Ngo, V. N. *et al.* Oncogenically active MYD88 mutations in human lymphoma. *Nature* **470**, 115–119 (2011).
34. Davis, R. E. *et al.* Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* **463**, 88–92 (2010).
35. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* **136**, 823–837 (2009).
36. Wayne, D. W. *Kolmogorov–Smirnov One-sample Test: Applied Nonparametric Statistics* 2nd edn 319–330 (PWS-Kent, 1990).
37. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
38. Alvarez, M. J. *et al.* Functional characterization of somatic mutations in cancer using network-based inference of protein activity. *Nat. Genet.* **48**, 838–847 (2016).
39. Lefebvre, C. *et al.* A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. *Mol. Syst. Biol.* **6**, 377 (2010).
40. Castro, M. A. *et al.* Regulators of genetic risk of breast cancer identified by integrative network analysis. *Nat. Genet.* **48**, 12–21 (2016).
41. Zhang, S. *et al.* Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. *Sci. Rep.* **5**, 16066 (2015).
42. Yepes, S., Torres, M. M. & Lopez-Kleine, L. Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia. *BMC Genomics* **16**, 1002 (2015).
43. Remo, A. *et al.* Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. *J. Transl. Med.* **13**, 138 (2015).
44. Fletcher, M. N. *et al.* Master regulators of FGFR2 signalling and breast cancer risk. *Nat. Commun.* **4**, 2464 (2013).
45. Tanaka, H. & Ogishima, S. Network biology approach to epithelial-mesenchymal transition in cancer metastasis: three stage theory. *J. Mol. Cell Biol.* **7**, 253–266 (2015).
46. Piao, G. *et al.* A computational procedure for identifying master regulator candidates: a case study on diabetes progression in Goto–Kakizaki rats. *BMC Syst. Biol.* **6** (Suppl. 1), S2 (2012).
47. Liang, Y. *et al.* Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. *J. Biol. Chem.* **287**, 33533–33544 (2012).
48. Califano, A., Butte, A. J., Friend, S., Ideker, T. & Schadt, E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. *Nat. Genet.* **44**, 841–847 (2012).
49. Pe'er, D. & Hachohen, N. Principles and strategies for developing network models in cancer. *Cell* **144**, 864–873 (2011).
50. Tovar, H., Garcia-Herrera, R., Espinal-Enriquez, J. & Hernandez-Lemus, E. Transcriptional master regulator analysis in breast cancer genetic networks. *Comput. Biol. Chem.* **59B**, 67–77 (2015).
51. Sartor, I. T., Zeidan-Chulia, F., Albanus, R. D., Dalmolin, R. J. & Moreira, J. C. Computational analyses reveal a prognostic impact of TULP3 as a transcriptional master regulator in pancreatic ductal adenocarcinoma. *Mol. Biosyst.* **10**, 1461–1468 (2014).
52. Lim, W. K., Lyashenko, E. & Califano, A. Master regulators used as breast cancer metastasis classifiers. *Pac. Symp. Biocomput.* **14**, 504–515 (2009).
53. Ikiz, B. *et al.* Dissecting the regulatory machinery of neurodegeneration in an *in vitro* model of amyotrophic lateral sclerosis. *Cell Rep.* **12**, 335–345 (2015).
54. Aubry, S. *et al.* Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression. *PLoS ONE* **10**, e0120352 (2015).
55. Brichta, L. *et al.* Identification of neurodegenerative factors using translome-regulatory network analysis. *Nat. Neurosci.* **18**, 1325–1333 (2015).

56. Repunte-Canonigo, V. *et al.* Identifying candidate drivers of alcohol dependence-induced excessive drinking by assembly and interrogation of brain-specific regulatory networks. *Genome Biol.* **16**, 68 (2015).
57. Kushwaha, R. *et al.* Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. *Stem Cells* **33**, 367–377 (2015).
58. Ravasi, T. *et al.* An atlas of combinatorial transcriptional regulation in mouse and man. *Cell* **140**, 744–752 (2010).
59. Basso, K. *et al.* Reverse engineering of regulatory networks in human B cells. *Nat. Genet.* **37**, 382–390 (2005).
60. ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* **447**, 799–816 (2007).
61. Sumazin, P. *et al.* An extensive microRNA-mediated network of RNA–RNA interactions regulates established oncogenic pathways in glioblastoma. *Cell* **147**, 370–381 (2011).
62. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. *Cell* **115**, 787–798 (2003).
63. Friedlander, M. R. *et al.* Discovering microRNAs from deep sequencing data using miRDeep. *Nat. Biotechnol.* **26**, 407–415 (2008).
64. Rual, J. F. *et al.* Towards a proteome-scale map of the human protein-protein interaction network. *Nature* **437**, 1173–1178 (2005).
65. Bandyopadhyay, S. *et al.* A human MAP kinase interactome. *Nat. Methods* **7**, 801–805 (2010).
66. Wang, K. *et al.* Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. *Nat. Biotechnol.* **27**, 829–839 (2009).
67. Zhang, Q. C. *et al.* Structure-based prediction of protein-protein interactions on a genome-wide scale. *Nature* **490**, 556–560 (2012).
68. AlQuraishi, M., Koytiger, G., Jenney, A., MacBeath, G. & Sorger, P. K. A multiscale statistical mechanical framework integrates biophysical and genomic data to assemble cancer networks. *Nat. Genet.* **46**, 1363–1367 (2014).
69. Faith, J. J. *et al.* Large-scale mapping and validation of *Escherichia coli* transcriptional regulation from a compendium of expression profiles. *PLoS Biol.* **5**, e8 (2007).
70. Friedman, N. Inferring cellular networks using probabilistic graphical models. *Science* **303**, 799–805 (2004).
71. Kundaje, A. *et al.* Learning regulatory programs that accurately predict differential expression with MEDUSA. *Ann. NY Acad. Sci.* **1115**, 178–202 (2007).
72. Kramer, A., Green, J., Pollard, J. R. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics* **30**, 523–530 (2014).
73. Maher, B. ENCODE: the human encyclopaedia. *Nature* **489**, 46–48 (2012).
74. Palomero, T. *et al.* NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. *Proc. Natl Acad. Sci. USA* **103**, 18261–18266 (2006).
75. Affara, M. *et al.* Vasohibin-1 is identified as a master-regulator of endothelial cell apoptosis using gene network analysis. *BMC Genomics* **14**, 23 (2013).
76. Werner, H. M., Mills, G. B. & Ram, P. T. Cancer systems biology: a peek into the future of patient care? *Nat. Rev. Clin. Oncol.* **11**, 167–176 (2014).
77. Saito, M. *et al.* BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. *Proc. Natl Acad. Sci. USA* **106**, 11294–11299 (2009).
78. Luscombe, N. M. *et al.* Genomic analysis of regulatory network dynamics reveals large topological changes. *Nature* **431**, 308–312 (2004).
79. Phillips, H. S. *et al.* Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* **9**, 157–173 (2006).
80. Brennan, C. W. *et al.* The somatic genomic landscape of glioblastoma. *Cell* **155**, 462–477 (2013).
81. Wapinski, O. L. *et al.* Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. *Cell* **155**, 621–635 (2013).
82. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
83. Chudnovsky, Y. *et al.* ZFX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. *Cell Rep.* **6**, 313–324 (2014).
84. Taylor, B. S. *et al.* Integrative genomic profiling of human prostate cancer. *Cancer Cell* **18**, 11–22 (2010).
85. US National Library of Medicine. *Clinicaltrials.gov* <https://clinicaltrials.gov/ct2/show/NCT02066532> (2014).
86. Tzoneva, G. *et al.* Activating mutations in the NTS52 nucleotidase gene drive chemotherapy resistance in relapsed ALL. *Nat. Med.* **19**, 368–371 (2013).
87. Woyach, J. A. *et al.* Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N. Engl. J. Med.* **370**, 2286–2294 (2014).
88. Flusberg, D. A. & Sorger, P. K. Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging. *Phys. Biol.* **10**, 035002 (2013).
89. Fenner, A. Prostate cancer: next-generation RNA sequencing identifies gene signature of neuroendocrine differentiation in prostate tumors. *Nat. Rev. Urol.* **9**, 8 (2012).
90. Van Vierbergh, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. *J. Clin. Invest.* **122**, 3398–3406 (2012).
91. Wei, G. *et al.* Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. *Cancer Cell* **10**, 331–342 (2006).
92. Rubin, E. H. & Gilliland, D. G. Drug development and clinical trials—the path to an approved cancer drug. *Nat. Rev. Clin. Oncol.* **9**, 215–222 (2012).
93. Shelanski, M. *et al.* A systems approach to drug discovery in Alzheimer's disease. *Neurotherapeutics* **12**, 126–131 (2015).
94. Schadt, E. E. *et al.* An integrative genomics approach to infer causal associations between gene expression and disease. *Nat. Genet.* **37**, 710–717 (2005).
95. Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. *Nat. Methods* **10**, 1108–1115 (2013).
96. Alvarez, M. J., Chen, J. C. & Califano, A. DIGGIT: a Bioconductor package to infer genetic variants driving cellular phenotypes. *Bioinformatics* **31**, 4032–4034 (2015).
97. Weinstein, I. B. Cancer. Addiction to oncogenes—the Achilles heel of cancer. *Science* **297**, 63–64 (2002).
98. Druker, B. J. *et al.* Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat. Med.* **2**, 561–566 (1996).
99. Wang, X., Haswell, J. R. & Roberts, C. W. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer—mechanisms and potential therapeutic insights. *Clin. Cancer Res.* **20**, 21–27 (2014).
100. Vazquez, M., Valencia, A. & Pons, T. Structure-PPi: a module for the annotation of cancer-related single-nucleotide variants at protein-protein interfaces. *Bioinformatics* **31**, 2397–2399 (2015).
101. Morris, J. P. t., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. *Nat. Rev. Cancer* **10**, 683–695 (2010).
102. Dhomen, N. & Marais, R. BRAF signaling and targeted therapies in melanoma. *Hematol. Oncol. Clin. North Am.* **23**, 529–545 (2009).
103. Davoli, A., Hoeschele, B. A. & Brown, T. L. Progression and treatment of HER2-positive breast cancer. *Cancer Chemother. Pharmacol.* **65**, 611–623 (2010).
104. Bansal, M. *et al.* A community computational challenge to predict the activity of pairs of compounds. *Nat. Biotechnol.* **32**, 1213–1222 (2014).
105. Woo, J. H. *et al.* Elucidating compound mechanism of action by network dysregulation analysis in perturbed cells. *Cell* **162**, 441–451 (2015).
106. Tallarida, R. J. An overview of drug combination analysis with isobolograms. *J. Pharmacol. Exp. Ther.* **319**, 1–7 (2006).
107. Patel, A. P. *et al.* Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **344**, 1396–1401 (2014).
108. Park, H. S. & Jun, C. H. A simple and fast algorithm for K-medoids clustering. *Expert Systems With Appl.* **36**, 3336–3341 (2009).
109. Lefebvre, C., Rieckhof, G. & Califano, A. Reverse-engineering human regulatory networks. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **4**, 311–325 (2012).
110. Linding, R. *et al.* Systematic discovery of *in vivo* phosphorylation networks. *Cell* **129**, 1415–1426 (2007).
111. Srivas, R. *et al.* Assembling global maps of cellular function through integrative analysis of physical and genetic networks. *Nat. Protoc.* **6**, 1308–1323 (2011).
112. Rhodes, D. R. *et al.* Mining for regulatory programs in the cancer transcriptome. *Nat. Genet.* **37**, 579–583 (2005).
113. Lachmann, A. *et al.* ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. *Bioinformatics* **26**, 2438–2444 (2010).
114. Needham, C. J., Bradford, J. R., Bulpitt, A. J. & Westhead, D. R. Inference in Bayesian networks. *Nat. Biotechnol.* **24**, 51–53 (2006).
115. Yeung, M. K., Tegner, J. & Collins, J. J. Reverse engineering gene networks using singular value decomposition and robust regression. *Proc. Natl Acad. Sci. USA* **99**, 6163–6168 (2002).
116. Martinez, M. R. *et al.* Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis. *Proc. Natl Acad. Sci. USA* **109**, 2672–2677 (2012).
117. Polynikis, A., Hogan, S. J. & di Bernardo, M. Comparing different ODE modelling approaches for gene regulatory networks. *J. Theor. Biol.* **261**, 511–530 (2009).
118. Stuart, J. M., Segal, E., Koller, D. & Kim, S. K. A gene-coexpression network for global discovery of conserved genetic modules. *Science* **302**, 249–255 (2003).
119. Horvath, S. & Dong, J. Geometric interpretation of gene coexpression network analysis. *PLoS Comput. Biol.* **4**, e1000117 (2008).
120. Jansen, R. *et al.* A Bayesian networks approach for predicting protein-protein interactions from genomic data. *Science* **302**, 449–453 (2003).
121. He, F., Balling, R. & Zeng, A. P. Reverse engineering and verification of gene networks: principles, assumptions, and limitations of present methods and future perspectives. *J. Biotechnol.* **144**, 190–203 (2009).
122. Stolovitzky, G., Prill, R. J. & Califano, A. Lessons from the DREAM2 Challenges. *Ann. NY Acad. Sci.* **1158**, 159–195 (2009).
123. Marbach, D. *et al.* Revealing strengths and weaknesses of methods for gene network inference. *Proc. Natl Acad. Sci. USA* **107**, 6286–6291 (2010).
124. Bussemaker, H. J., Li, H. & Siggia, E. D. Regulatory element detection using correlation with expression. *Nat. Genet.* **27**, 167–171 (2001).
125. Fiedler, D. *et al.* Phosphorylation organization of the *S. cerevisiae* phosphorylation network. *Cell* **136**, 952–963 (2009).
126. Mani, K. M. *et al.* A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. *Mol. Syst. Biol.* **4**, 169 (2008).
127. Ideker, T. & Krogan, N. J. Differential network biology. *Mol. Syst. Biol.* **8**, 565 (2012).
128. Barrios-Rodiles, M. *et al.* High-throughput mapping of a dynamic signaling network in mammalian cells. *Science* **307**, 1621–1625 (2005).
129. Saez-Rodriguez, J. *et al.* Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. *Cancer Res.* **71**, 5400–5411 (2011).
130. Menashe, I. *et al.* Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. *Cancer Res.* **70**, 4453–4459 (2010).
131. Laoukili, J. *et al.* FoxM1 is required for execution of the mitotic programme and chromosome stability. *Nature Cell Biol.* **7**, 126–136 (2005).
132. Basu, A. *et al.* An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. *Cell* **154**, 1151–1161 (2013).
133. Flusberg, D. A., Roux, J., Spencer, S. L. & Sorger, P. K. Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. *Mol. Biol. Cell* **24**, 2186–2200 (2013).
134. Roschewski, M., Staudt, L. M. & Wilson, W. H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. *Nat. Rev. Clin. Oncol.* **11**, 12–23 (2014).

#### Acknowledgements

This work was supported by the National Cancer Institute (NCI) Cancer Target Discovery and Development Program (1U01CA168426), NCI Outstanding Investigator Award (R35CA197745) for A.C., NCI Research Centers for Cancer Systems Biology Consortium (1U54CA209997) and the NIH instrumentation grants (S10OD012351 and S10OD021764).

#### Competing interests statement

The authors declare [competing interests](#): see Web version for details.

#### DATABASES

CCLLE: <http://software.broadinstitute.org/software/cprg/?q=node/11>

#### FURTHER INFORMATION

The Cancer Genome Atlas: <http://cancergenome.nih.gov>

ALL LINKS ARE ACTIVE IN THE ONLINE PDF